Giovanni M. Paganelli
Via P. Maroncelli N. 40
Meldola, 47014, Italy
Meldola, 47014, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 120 publications
PSMA expression: enhancing prostate cancer diagnosis at the biopsy stage.
Journal: Minerva urology and nephrology
Published: July 07, 2026
Prostate-Specific Membrane Antigen (PSMA): A Potential Theranostic Biomarker in Breast Cancer.
Journal: Biomedicines
Published: December 23, 2025
Coupling Adoptive Cell Therapy with Boron Neutron Capture Therapy: Using Functional Tumor-Infiltrating Lymphocytes for Tumor Delivery of Boron Carbide Nanoparticles.
Journal: ACS nano
Published: December 05, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 14, 2025
FAP inhibitors: are we really using the best method to evaluate the residence time?
Journal: European journal of nuclear medicine and molecular imaging
Published: February 25, 2025
Do we need dosimetry for the optimization of theranostics in CNS tumors?
Journal: Neuro-oncology
Published: October 01, 2024
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 26, 2024
Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study.
Journal: Neuroendocrinology
Published: June 12, 2024
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers.
Journal: Cancer treatment reviews
Published: December 19, 2023
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 27, 2023
Radioligand therapies in cancer: mapping the educational landscape in Europe.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 03, 2023
Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors.
Journal: Frontiers in oncology
Published: January 02, 2023
Last Updated: 09/26/2026